Skip to main content
Psyence Group Inc. logo

Psyence Group Inc. — Investor Relations & Filings

Ticker · PSYG ISIN · CA74449Q2053 LEI · 549300RPEOIVSD0MJC07 CSE Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2024-11-04 Regulatory Filings
Country CA Canada
Listing CSE PSYG

About Psyence Group Inc.

https://psyence.com/

Psyence Group Inc. is a science-led life science biotechnology company focused on the research, cultivation, and production of natural psychedelics and nature-based compounds. The company develops innovative, safe, and effective solutions for mental health. Its core clinical division, Psyence Therapeutics (now part of Psyence Biomedical Ltd.), pioneers the use of natural psilocybin formulations and treatment protocols, primarily targeting anxiety and depression within the context of palliative care. Supporting this effort, the company operates one of the world's first federally licensed, ISO22000 certified psilocybin cultivation and production facilities. Furthermore, Psyence Function markets a range of non-psychoactive functional mushroom wellness products utilizing adaptogens.

Recent filings

Filing Released Lang Actions
Other material contracts - English.pdf
Regulatory Filings
2024-11-04 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a previously announced disposal of a stake in PsyLabs and a debt-for-equity swap agreement between Psyence Group and Psyence Biomed. It details the transaction terms, strategic partnerships, and forward-looking statements. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document focuses on a capital transaction and financing activity involving share issuance and debt conversion. It is not an annual report, earnings release, or management discussion. The content fits the category of Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes.
2024-10-31 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a press release announcing the recruitment of a second clinical trial site for an ongoing Phase IIb clinical trial by Psyence Biomedical. It provides details about the trial progress, future expectations for topline data, and background information about the company and the clinical site. There are no financial statements, regulatory filings, or detailed financial data presented. The document is primarily an update on clinical trial progress and company activities, typical of a Capital/Financing Update or general corporate announcement. However, since it focuses on clinical trial progress and recruitment rather than fundraising or capital structure changes, it does not fit the Capital/Financing Update (CAP) category perfectly. It is not a regulatory filing or report publication announcement. Given the nature of the announcement as a corporate update on clinical trial progress, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-10-25 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Psyence Group has entered into a debt-for-equity swap agreement with its NASDAQ-listed associate, Psyence Biomedical. The content focuses on the terms of the debt swap, the strategic rationale, regulatory exemptions relied upon, and forward-looking statements. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is an update on a financing transaction involving capital structure changes (debt converted to equity). It is not an annual or interim report, audit report, or earnings release. It is not a regulatory filing in the sense of officer certifications or compliance documents. The primary subject is a financing transaction announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (8827 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2024-10-14 English
Notice of the meeting and record date - English.pdf
AGM Information Classification · 90% confidence The document is a notice regarding the upcoming Annual General and Special Meeting of Psyence Group Inc., including details such as meeting date, record date, and voting information. It does not contain the actual meeting materials or presentations but rather announces the meeting and related administrative details. The document length is short (1108 characters), and it serves as a notification rather than the AGM materials themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices related to it.
2024-10-11 English
Other material contracts - English.pdf
Regulatory Filings
2024-09-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.